Bausch+Lomb Results Presentation Deck
1Q22 Highlights
Bausch + Lomb
+1% 1Q22 Reported Revenue
+5% 1Q22 Organic Revenue ¹,2
+4% 1Q22 Constant Currency¹
Ophthalmic
Pharmaceuticals
17%
Surgical
20%
BAUSCH + LOMB
Vision Care
63%
Continued
Momentum in
Key Portfolios
-33%
largest market share in U.S.
consumer eye care³, strong
growth in vitamins & redness
relief
+13%
Surgical organic revenue
growth ¹,2, market recovery
and backlog tailwinds
Investing in
Categories Growing
Faster Than Market
5. 2020-2030 B+L Brand Estimate, Daily Disposable Single Vision Spherical Retail Sales (S)
6. Macular edema.
7. 2021 Clarivate
~2x
increase in Daily SiHy
U.S. (unit) market share
since 1Q214
-10%
estimated 2019-30
annual U.S. market growth
in Daily SiHy lens category5
1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
2. Organic growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations
Based on Dollar Sales from IRI National Consumer Panel Data, Total US All Outlet Sales, Latest 13 Weeks Ending 03-27-22
3.
4. GfK U.S. Daily SiHy Shares by Manufacturer, Unit Shares, Rolling 13 Months (March 2022)
Expanding Into
New Product
Categories
XIPERE
(triamcinolone acetonide
injectable suspension) 40 mg/mL
first and only therapy to
use suprachoroidal space
~$433M ¹
forecasted 2022 uveitis
market in the U.S. - with
ME6 associated with uveitis
being a portion of that
market
6View entire presentation